Combined pre-treatment and middle-treatment Epstein-Barr virus DNA load contributes to prognostication and treatment modification in nasopharyngeal carcinoma patients.
Kaiqi LanJingrong MaoXuesong SunSuchen LiSiyi XieRui SunSailan LiuHai-Qiang MaiPublished in: Therapeutic advances in medical oncology (2024)
cisplatin may be adequate to achieve satisfactory survival outcomes in the high-risk group.